Abby Hardy, Author at BioTuesdays

Developments

FDA approves Urogen Pharma’s urothelial cancer drug

The FDA approved UroGen Pharma’s (NASDAQ:URGN) mitomycin gel for the treatment of low-grade upper tract urothelial cancer (UTUC). The gel, which will be marketed under the brand name Jelmyto, inhibits DNA transcription...

April 15, 2020

Developments

Chembio gets FDA emergency use authorization for serological COVID-19 test

The FDA granted emergency use authorization to Chembio Diagnostics’ (NASDAQ:CEMI) dual path platform (DPP) COVID-19 system. The system is a serological point-of-care test and analyzer that provides numerical readings...

April 15, 2020

Executive Moves

TerrAscend appoints Jason Ackerman as permanent CEO; CFO to step down

Jason Ackerman TerrAscend (OTCQX:TRSSF) appointed Jason Ackerman as CEO and reported that its CFO, Adam Kozak, will step down as the company relocates its financial operations from Toronto to New York City. Mr. Ackerman...

April 14, 2020

Executive Moves

Five Prime Therapeutics appoints industry leader, Tom Civik, as CEO

Tom Civik Five Prime Therapeutics (NASDAQ:FPRX) appointed Tom Civik as president, CEO and a director. William Ringo, who served as Five Prime’s chairman and interim CEO since September 2019, will step down as CEO and...

April 14, 2020

Feature

NanoViricides targeting multiple types of viral infection with nanomedicine platform

Using its nanomedicine platform and the capabilities of its cGMP manufacturing facility, NanoViricides (NYSE American: NNVC) is developing therapeutics for a variety of viral infections, including herpes simplex viruses...

April 14, 2020

Developments

Bellerophon submits IND for INOpulse inhaled nitric oxide for COVID-19

Bellerophon Therapeutics (NASDAQ:BLPH) submitted an IND to the FDA to study INOpulse, a pulsed nitric oxide (NO) system, for the treatment of patients with COVID-19. The IND follows the FDA’s allowance of treatment with...

April 9, 2020

Developments

MEI Pharma gets FDA fast track designation for follicular lymphoma

MEI Pharma’s (NASDAQ:MEIP) ME-401 received FDA fast track designation for the treatment of patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies. The company is...

March 31, 2020

Feature

Amidst a global pandemic, two biotech companies offer innovative solutions

Since COVID-19 was first identified in China late last year, researchers have been working tirelessly to develop diagnostics, therapeutics and vaccines in an effort to prevent the spread of the SARS-CoV-2 virus. Many...

March 31, 2020

Developments

Profound Medical’s TULSA-PRO now available at Georgia’s renowned Busch Center

Georgia’s renowned Busch Center is now offering Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA-PRO procedure to treat unhealthy prostate tissue. The technology, which was cleared by the FDA in August 2019, provides...

March 26, 2020

Developments

Prevail Therapeutics gets FDA fast track designation for frontotemporal dementia gene therapy

Prevail Therapeutics (NASDAQ:PRVL) received FDA fast track designation for PR006, a gene therapy candidate designed to slow the progression of frontotemporal dementia with a GRN mutation. Frontotemporal dementia is the...

March 24, 2020

Author - Abby Hardy

FDA approves Urogen Pharma’s urothelial cancer drug

Chembio gets FDA emergency use authorization for serological COVID-19 test

TerrAscend appoints Jason Ackerman as permanent CEO; CFO to step down

Five Prime Therapeutics appoints industry leader, Tom Civik, as CEO

NanoViricides targeting multiple types of viral infection with nanomedicine platform

Bellerophon submits IND for INOpulse inhaled nitric oxide for COVID-19

MEI Pharma gets FDA fast track designation for follicular lymphoma

Amidst a global pandemic, two biotech companies offer innovative solutions

Profound Medical’s TULSA-PRO now available at Georgia’s renowned Busch Center

Prevail Therapeutics gets FDA fast track designation for frontotemporal dementia gene therapy

Subscribe